ATE236652T1 - Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem - Google Patents

Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem

Info

Publication number
ATE236652T1
ATE236652T1 AT96942947T AT96942947T ATE236652T1 AT E236652 T1 ATE236652 T1 AT E236652T1 AT 96942947 T AT96942947 T AT 96942947T AT 96942947 T AT96942947 T AT 96942947T AT E236652 T1 ATE236652 T1 AT E236652T1
Authority
AT
Austria
Prior art keywords
igf
nervous system
central nervous
treatment
system diseases
Prior art date
Application number
AT96942947T
Other languages
English (en)
Inventor
Douglas N Ishii
Original Assignee
Aurogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurogen Inc filed Critical Aurogen Inc
Application granted granted Critical
Publication of ATE236652T1 publication Critical patent/ATE236652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96942947T 1995-12-13 1996-12-11 Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem ATE236652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57180295A 1995-12-13 1995-12-13
PCT/US1996/019663 WO1997021449A1 (en) 1995-12-13 1996-12-11 Method for effecting changes in the central nervous system by administration of igf-i or igf-ii

Publications (1)

Publication Number Publication Date
ATE236652T1 true ATE236652T1 (de) 2003-04-15

Family

ID=24285123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942947T ATE236652T1 (de) 1995-12-13 1996-12-11 Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem

Country Status (7)

Country Link
EP (1) EP0874641B1 (de)
JP (1) JP2000514038A (de)
AT (1) ATE236652T1 (de)
CA (1) CA2240327C (de)
DE (1) DE69627379T2 (de)
ES (1) ES2196194T3 (de)
WO (1) WO1997021449A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532821A1 (en) * 2003-07-29 2005-02-17 Ares Trading S.A. Use of human growth hormone in multiple system atrophy
ES2322685B2 (es) * 2006-11-21 2010-03-15 Universidad De Malaga Utilizacion de dosis bajas de igf-ii en el envejecimiento por sus efectos neuroprotectores y hepatoprotectores.
WO2013050529A2 (en) * 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
ES2927133B2 (es) * 2021-04-28 2023-12-29 Univ Malaga Tratamiento para la enfermedad de Parkinson

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
EP0597033B1 (de) * 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders

Also Published As

Publication number Publication date
WO1997021449A1 (en) 1997-06-19
EP0874641A1 (de) 1998-11-04
JP2000514038A (ja) 2000-10-24
CA2240327A1 (en) 1997-06-19
DE69627379D1 (de) 2003-05-15
ES2196194T3 (es) 2003-12-16
EP0874641B1 (de) 2003-04-09
CA2240327C (en) 2005-07-12
DE69627379T2 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
ATE459335T1 (de) Verfahren zur behandlung von augenerkrankungen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DE69913665D1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE60121808D1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
EP0573568A4 (en) Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
DE69232008D1 (de) Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
ATE193020T1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
DE69636147D1 (de) Verfahren zur herstellung von phosphorothioat-oligomeren
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
AU8658298A (en) Method for preventing and treating hearing loss using a neurturin protein product
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69606960D1 (de) Adsorbent, Verfahren zu dessen Herstellung und Methode zur Behandlung von Fruchtsaft
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69627379D1 (de) Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
AU4876196A (en) A process for the preparation of factor ix from biological sources
DE3787437D1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
ATE263573T1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
EP0495998A4 (de)
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
BG101983A (en) Substituted phenylamidines, medicamentous forms containing them and mehtod for their preparation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties